Expanded Sales of Copolyesters and Pharmaceuticals,
Growth Contribution from SK Bioscience
Core Chemical and Pharmaceutical Businesses Grow
Operating Loss Narrows by 45 Billion Won
Profitability on the Road to Recovery Despite Industry Slump

Despite a challenging business environment, including a global chemical industry downturn and rising cost burdens, SK Chemicals achieved both sales growth and improved profitability trends, driven by its core chemical and pharmaceutical businesses and the growth of its subsidiary SK Bioscience.

SK Chemicals headquarters in Pangyo, Seongnam, Gyeonggi Province. Provided by SK Chemicals.

SK Chemicals headquarters in Pangyo, Seongnam, Gyeonggi Province. Provided by SK Chemicals.

View original image

On a consolidated basis, SK Chemicals posted sales of 2.3652 trillion won and an operating loss of 200 million won in 2025.


Sales of key products such as copolyesters and pharmaceuticals increased, and the external growth of SK Bioscience also contributed, resulting in a 36.2% year-on-year increase in revenue. In particular, as the profitability of SK Bioscience improved, the operating loss narrowed by approximately 45 billion won compared with the previous year.


On a separate basis, revenue came to 1.4404 trillion won, up 7.45% from a year earlier, but operating profit fell 13.84% to 95.7 billion won due to higher raw material costs.



A company official said, "Even in a challenging market environment of global economic slowdown and industry downturn, we are continuing our top-line growth by advancing the competitiveness of our core businesses," adding, "We will establish a stable operating system that can proactively respond to market volatility and will continue to strengthen our fundamental competitiveness and improve management efficiency."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing